EMDR vs MDMA-Assisted Therapy: What Research Shows

EMDR and MDMA-assisted therapy both target PTSD but work in opposite ways. EMDR is a therapist-led psychotherapy using bilateral stimulation to reprocess memories, recommended by treatment guidelines since 2013. MDMA-assisted therapy pairs a Schedule I drug with therapy sessions; despite promising trial results, the FDA rejected it in 2024, and it remains unavailable outside research settings in the US.

If you’ve been researching PTSD treatment, you’ve probably noticed these two names come up together often. That pairing undersells how different they are: one is an established, therapist-delivered psychotherapy you can access today; the other is an investigational drug treatment a major regulator just declined to approve. Here’s what each one involves, what the research shows, and where they stand right now.

What is MDMA-assisted therapy?

MDMA (3,4-methylenedioxymethamphetamine) was first synthesized in 1912 by a Merck chemist, though its psychoactive effects went unnoticed for decades. After chemist Alexander Shulgin resynthesized it in the 1970s, some psychotherapists began giving it to clients to ease communication during sessions, a practice that continued quietly until MDMA’s rise as the recreational drug “ecstasy” led the DEA to place it in Schedule I in 1985, the category for substances with no accepted medical use and high abuse potential.

Clinical interest resumed in the 2000s, and the FDA granted MDMA-assisted therapy Breakthrough Therapy designation for PTSD in 2017. “MDMA-assisted therapy” (sometimes shortened to MDMA-AT) describes a specific manualized protocol, not simply taking the drug: three 90-minute preparatory sessions with two co-therapists, then up to three dosing sessions spaced roughly a month apart, each lasting 6 to 8 hours and followed by a set of 90-minute integration sessions to talk through what came up, with a supervised overnight gap before the next morning’s integration session.

Its evidence base is real. Two placebo-controlled Phase 3 trials, sponsored by MAPS/Lykos Therapeutics and published in Nature Medicine, found meaningfully larger drops in PTSD symptoms with MDMA-assisted therapy than with the same therapy structure plus placebo. But in August 2024, the FDA declined to approve it, and no MDMA product currently has any approved medical use in the United States. Australia is the one notable exception: its Therapeutic Goods Administration reclassified MDMA in 2023, letting specially authorized psychiatrists prescribe it for PTSD outside a research trial. No equivalent pathway exists in the US.

What is EMDR?

EMDR (Eye Movement Desensitization and Reprocessing) was developed by psychologist Dr. Francine Shapiro in 1987. Its theory, the Adaptive Information Processing model, holds that PTSD and related distress often come from memories stored in a raw, unprocessed form; process the memory, and the distress attached to it tends to ease too.

In a session, you briefly hold a distressing memory in mind while following sets of bilateral stimulation: alternating eye movements, tones, or taps. It’s a structured, eight-phase protocol moving from history-taking through assessment, desensitization, installation, and reevaluation. You stay verbal and oriented to the room throughout, unlike the hours-long MDMA session described above.

Becoming an EMDR clinician requires an EMDRIA-approved basic training, about 50 hours on top of an existing clinical license. Sessions typically run 60 to 90 minutes.

EMDR vs MDMA-assisted therapy at a glance

	EMDR	MDMA-Assisted Therapy
Developed	1987, by psychologist Dr. Francine Shapiro	Synthesized 1912; studied for PTSD from the 1970s; still not FDA-approved
What it is	A structured psychotherapy	An investigational drug paired with structured psychotherapy
What you do in session	Briefly recall a memory while following bilateral stimulation, staying verbal throughout	Take MDMA under two clinicians’ supervision for hours, moving between talking and quiet inward focus
Session length	60–90 minutes	~90-minute prep/integration sessions; dosing sessions run 6–8 hours
Typical course	Often several sessions per target memory	3 preparatory sessions, up to 3 dosing sessions, 9 integration sessions
FDA-approved for	Not applicable; a psychotherapy, not a drug	Nothing; MDMA has no FDA-approved use of any kind
PTSD guideline status	Recommended (WHO 2013); strongly recommended (VA/DoD 2023); conditionally recommended (APA 2017)	Insufficient evidence to recommend for or against (VA/DoD 2023)
Regulatory status	Not a controlled substance	Schedule I controlled substance; FDA issued a Complete Response Letter in August 2024
Practitioner	Licensed therapist with EMDRIA basic training	Two co-therapists per dosing session in trials; no legal prescribing pathway in the US
Can you self-administer it?	Core technique adapts to solo practice	No; illegal outside an authorized US clinical trial

How do the sessions feel different?

EMDR keeps you present and narrating. Bilateral stimulation runs in short sets, typically 20 to 30 seconds, pausing so the clinician can ask what surfaced, while you stay oriented to the room and largely in control of the pace.

MDMA sessions unfold very differently. Once the drug takes hold, participants in the Phase 3 trials described emotional openness and a reduced fear response, often spending portions of the session lying down with eyeshades and music, then talking through material with the co-therapists as it arises. A single dosing day is a major time commitment, and most people feel drained the next day.

Some find MDMA’s softened fear response makes it easier to approach overwhelming memories. Others would rather stay fully present and in control the way EMDR asks.

What does the research actually show?

The two sit at very different points in the evidence pipeline, and that gap matters more here than in most comparisons like this.

EMDR’s evidence centers on PTSD and carries real guideline weight: the World Health Organization’s 2013 guideline and the 2023 VA/DoD clinical practice guideline both recommend it, while the APA’s 2017 guideline recommends it conditionally. See Does EMDR Work? What the Evidence Actually Says for a fuller look, or EMDR and PTSD if that’s specifically what brought you here.

MDMA-assisted therapy’s headline results are genuinely strong. In the first Phase 3 trial, published in Nature Medicine in 2021, 90 adults with severe PTSD were randomized to MDMA or placebo, both paired with the same therapy structure; 67% of the MDMA group no longer met PTSD diagnostic criteria afterward, compared with 32% of the placebo group. The confirmatory Phase 3 trial, published in Nature Medicine in 2023, found a similar pattern in 104 randomized participants: 71.2% of the MDMA group no longer met PTSD criteria, versus 47.6% of the placebo group.

Those numbers explain the attention. But strong trial results didn’t translate into approval. At a June 2024 meeting, the FDA’s Psychopharmacologic Drugs Advisory Committee reviewed that same trial data and voted 2 to 9 against the idea that it had shown clear effectiveness, and 1 to 10 against the idea that its benefits outweighed its risks. The concerns centered on “functional unblinding”: MDMA’s effects are hard to miss, so participants and therapists could often tell who’d received it, which can inflate results through expectancy alone. Reviewers also flagged inconsistent side-effect tracking across trial sites, and a documented case of therapist misconduct in an earlier, non-pivotal trial.

On August 9, 2024, the FDA issued a Complete Response Letter declining to approve MDMA-assisted therapy, saying the submitted data wasn’t sufficient and asking for an additional Phase 3 trial. Lykos Therapeutics has since undergone major restructuring and says it intends to pursue that trial. That leaves MDMA-assisted therapy exactly where the VA/DoD’s 2023 guideline already placed it: insufficient evidence either way, well behind where EMDR already sits.

Is MDMA-assisted therapy safe?

Safety here has two layers: the drug itself, and the state of the evidence about it.

MDMA raises heart rate and blood pressure and carries a real, if generally low, risk of dangerous overheating outside a monitored setting. It also interacts seriously with other serotonin-affecting medications: trial protocols require tapering off SSRIs and similar antidepressants well before a dosing session, partly for safety and partly because recent SSRI use appears to blunt MDMA’s effects. If you take an SSRI or any other psychiatric medication, never start, stop, or change it on your own; that decision belongs with your prescriber.

The evidence-quality concerns above matter for safety too. When a trial can’t reliably blind participants, it’s harder to separate the drug’s real effect from expectation, and harder to know how consistently side effects were tracked. That’s largely why the FDA wants another trial, not proof MDMA-assisted therapy doesn’t help, but evidence the current data can’t yet rule out how much of the benefit came from something other than the drug itself.

If you’re ever in crisis, our crisis resources page is here, and in the US you can also call or text 988 anytime.

Which one fits you?

EMDR may fit better if:

• You want an approach with over a decade of guideline support and a clear path to a licensed provider today.
• You’d rather stay verbal and in control of the pace throughout treatment.
• Committing a full day, plus recovery time, to a single session isn’t realistic for your life right now.

MDMA-assisted therapy may fit better if:

• You’ve tried multiple guideline-recommended PTSD treatments without enough relief.
• You’re willing and able to enroll in a clinical trial, the only legal route in the US today.
• You’re comfortable with a drug-assisted, hours-long session and the current uncertainty around approval.

Worth saying plainly: both are treatments for a diagnosed, serious condition, not everyday stress, and that decision belongs with a psychiatrist or trauma-trained therapist who knows your full history. For another investigational, drug-assisted comparison, see EMDR vs Ketamine-Assisted Therapy.

Can you practice either one on your own?

Here the two diverge completely.

MDMA-assisted therapy has no legal self-guided version in the US. MDMA is a Schedule I controlled substance; using it outside an authorized clinical trial is illegal, and doing so without the medical monitoring the research protocol requires is unsafe. There’s no lower-stakes way to try a piece of it alone, the way EMDR allows.

EMDR is different, but only for a much smaller job than either treatment here is meant for. Its core ingredient, bilateral stimulation, can be practiced solo for everyday stress, never as a stand-in for treating diagnosed PTSD. Read all three steps below before you try it.

1. Stabilize first. Spend a minute somewhere calm before working with anything. Picture a real or imagined calm place, or try simple grounding: name what you can see around you, feel your feet on the floor, slow your exhale.

2. Go slow, one moment at a time. Pick a single small, recent stressor, not a diagnosed condition or a heavy trauma memory. Keep the session brief.

3. Know your stop point. If distress rises above a 7 out of 10 and won’t settle, stop, ground yourself, and consider working with a professional instead of continuing alone. Never start, stop, or change any medication because of this practice; that stays between you and your prescriber.

With that in place, our beginner’s guide to self-guided bilateral stimulation walks through a full session step by step. Here’s the short version, for one everyday moment:

• Name it and rate it. On a 0–10 scale, how strong is the feeling right now?
• Bring one specific moment to mind, not a whole condition, just this one piece of stress.
• Add bilateral stimulation. Move your eyes slowly left and right for 20–30 seconds, or tap alternating knees or shoulders.
• Pause and notice what shifted, without forcing anything.
• Repeat 3 to 5 short rounds, checking your number again after each one.

EmEase, a self-guided EMDR app, offers this same technique in a guided, paced format if you’d rather not track the timing yourself; you can try it at app.emease.com. It’s a wellness practice inspired by EMDR therapy, not a treatment for PTSD and not a substitute for either approach in this comparison. Is self-guided EMDR safe? covers that line in more detail.

The bottom line

These two aren’t really rivals for the same choice today. EMDR is an established, guideline-recommended psychotherapy you can start with a licensed therapist now, with a core technique that scales down safely to solo practice for everyday stress. MDMA-assisted therapy has strong Phase 3 results behind it, but the FDA found the evidence insufficient in 2024, and it remains a Schedule I substance available only through clinical trials.

If PTSD is what brought you here, that conversation belongs with a psychiatrist or trauma-trained therapist who can weigh your full history and, if relevant, help you find a trial. For the everyday stress around that bigger picture, bilateral stimulation, EMDR’s core technique, is the piece worth practicing on your own today.

Frequently asked questions

Is MDMA-assisted therapy FDA-approved for PTSD?

No. In August 2024, the FDA issued a Complete Response Letter declining to approve it, after its advisory committee voted against the treatment’s shown effectiveness. The FDA asked for an additional Phase 3 trial before it will reconsider. MDMA currently has no FDA-approved use of any kind.

Is MDMA legal to use for PTSD treatment?

Not outside a clinical trial in the US. MDMA is a Schedule I controlled substance under the DEA, the category for drugs with no accepted medical use. Australia is a rare exception, letting specially authorized psychiatrists prescribe it for PTSD since 2023 under strict conditions; no equivalent legal pathway exists in the US.

What did the MDMA-assisted therapy trials actually find?

Two Phase 3 trials found real benefit. In the 2021 trial, 67% of the MDMA group no longer met PTSD criteria afterward, versus 32% on placebo. The 2023 confirmatory trial found 71.2% versus 47.6%. Both trials paired MDMA with the same structured therapy given to the placebo group.

Why did the FDA reject MDMA-assisted therapy if the trials looked positive?

Reviewers questioned how much of the effect reflected the drug itself versus participants and therapists correctly guessing who received it, since MDMA’s effects are hard to hide. They also cited gaps in tracking side effects across sites and a documented case of therapist misconduct in an earlier trial.

Can you combine EMDR and MDMA-assisted therapy?

There’s no published research combining them directly, and MDMA-assisted therapy isn’t available outside clinical trials in the US regardless. If you’re in an MDMA trial or considering one, that’s a conversation for the study team and your own prescriber, not something to layer with self-directed EMDR practice on your own.

Can you do MDMA-assisted therapy on your own?

No. MDMA is a Schedule I controlled substance, and using it outside an authorized clinical trial is illegal and unsafe without the medical monitoring built into the research protocol. EMDR’s core technique, bilateral stimulation, is different: it’s built to translate into solo practice for everyday stress, not a controlled substance at all.